Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Langsenlehner, T; Thurner, EM; Krenn-Pilko, S; Langsenlehner, U; Stojakovic, T; Gerger, A; Pichler, M.
Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.
World J Urol. 2015; 33(11):1661-1667
Doi: 10.1007/s00345-015-1494-7
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Langsenlehner Tanja
- Co-Autor*innen der Med Uni Graz
-
Gerger Armin
-
Krenn-Pilko Sabine
-
Langsenlehner Uwe
-
Pichler Martin
-
Stojakovic Tatjana
-
Thurner Eva-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Recent studies have expanded the concept that the systemic inflammatory response has an important role in the progression of several solid tumors. The neutrophil-to-lymphocyte ratio (NLR), an easily determinable marker of systemic inflammation, has been associated with clinical outcome in various cancer entities. In the present study, we validated the prognostic relevance of an elevated NLR in a cohort of European prostate cancer patients.
Data from 415 consecutive prostate cancer patients treated with 3D conformal radiotherapy at a single tertiary academic center from 1999 to 2007 were included in this retrospective study. Clinical progression-free survival (PFS), distant metastases-free survival (DMFS), and overall survival (OS) were assessed using the Kaplan-Meier method. To evaluate the prognostic relevance, univariate and multivariate Cox regression models were performed for each end point.
Based on previously published studies, an NLR ≥ 5 was selected as cutoff value for external validation. Multivariate analysis identified an increased NLR as an independent prognostic factor for clinical PFS [hazard ratio (HR) 3.09, 95 % CI 1.64-5.82, p < 0.001], DMFS (HR 3.51, 95 % CI 1.80-6.85, p < 0.001), and OS (HR 2.16, 95 % CI 1.17-3.99, p = 0.013).
The NLR seems to represent an independent prognostic marker and should be considered for future individual risk assessment in patients with prostate cancer.
- Find related publications in this database (using NLM MeSH Indexing)
-
Aged -
-
Aged - epidemiology
-
Disease Progression -
-
Disease-Free Survival -
-
Follow-Up Studies -
-
Humans -
-
Kaplan-Meier Estimate -
-
Leukocyte Count -
-
Lymphocytes - pathology
-
Male -
-
Neutrophils - pathology
-
Prognosis -
-
Proportional Hazards Models -
-
Prostatic Neoplasms - diagnosis
-
Prostatic Neoplasms - epidemiology
-
Retrospective Studies -
-
Survival Rate - trends
- Find related publications in this database (Keywords)
-
Prostate cancer
-
Prognosis
-
Inflammation
-
Neutrophil-to-lymphocyte ratio